[go: up one dir, main page]

BR9710115A - Processo para aplicar partìculas sólidas de um medicamento em superfìcies de mucosa das cavidade nasais, composição aquosa farmacêutica, e , processo de preparação de uma composição aquosa farmacêutica. - Google Patents

Processo para aplicar partìculas sólidas de um medicamento em superfìcies de mucosa das cavidade nasais, composição aquosa farmacêutica, e , processo de preparação de uma composição aquosa farmacêutica.

Info

Publication number
BR9710115A
BR9710115A BR9710115-0A BR9710115A BR9710115A BR 9710115 A BR9710115 A BR 9710115A BR 9710115 A BR9710115 A BR 9710115A BR 9710115 A BR9710115 A BR 9710115A
Authority
BR
Brazil
Prior art keywords
composition
pharmaceutical composition
aqueous pharmaceutical
mucosal surfaces
preparing
Prior art date
Application number
BR9710115-0A
Other languages
English (en)
Other versions
BR9710115B1 (pt
Inventor
Soo-Il Kim
Original Assignee
Rorer Pharm Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24722901&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9710115(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rorer Pharm Prod Inc filed Critical Rorer Pharm Prod Inc
Publication of BR9710115A publication Critical patent/BR9710115A/pt
Publication of BR9710115B1 publication Critical patent/BR9710115B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
    • B05B11/00—Single-unit hand-held apparatus in which flow of contents is produced by the muscular force of the operator at the moment of use
    • B05B11/01—Single-unit hand-held apparatus in which flow of contents is produced by the muscular force of the operator at the moment of use characterised by the means producing the flow
    • B05B11/10—Pump arrangements for transferring the contents from the container to a pump chamber by a sucking effect and forcing the contents out through the dispensing nozzle
    • B05B11/1001—Piston pumps
    • B05B11/1016—Piston pumps the outlet valve having a valve seat located downstream a movable valve element controlled by a pressure actuated controlling element
    • B05B11/1018—Piston pumps the outlet valve having a valve seat located downstream a movable valve element controlled by a pressure actuated controlling element and the controlling element cooperating with means for opening or closing the inlet valve

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"PROCESSO PARA APLICAR PARTìCULAS SóLIDAS DE UM MEDICAMENTO EM SUPERFìCIES DE MUCOSA DAS CAVIDADES NASAIS, COMPOSIçãO AQUOSA FARMACêUTICA, E, PROCESSO DE PREPARAçãO DE UMA COMPOSIçãO AQUOSA FARMACêUTICA". Uma composição aquosa farmacêutica que é capaz de ser pulverizada dentro da cavidade nasal de um indivíduo e que compreende: (A) uma quantidade farmaceuticamente efetiva de partículas sólidas de medicamento que é efetivo no tratamento de uma condição corporal em virtude de sua presença sobre as superfícies de mucosa da cavidade nasal; e (B) um agente de suspensão em uma quantidade efetiva para manter as citadas partículas uniformemente dispersadas na composição e para fornecer à composição as seguintes propriedades tixotrópicas: (i) a viscosidade de posição na forma não-cisalhada é relativamente elevada, com a composição se apresentando na forma semelhante a gel; (ii) à medida que a composição é submetida ao cisalhamento (agitação) na preparação para pulverização, a viscosidade da composição torna-se relativamente baixa e tal que a composição na forma de uma névoa flui prontamente para dentro das passagens nasais para ser depositada sobre as superfícies de mucosa da cavidade nasal; e (iii) na forma depositada sobre as superfícies de mucosa, a viscosidade da composição é relativamente elevada e tal que ela resiste à sua remoção das superfícies de mucosa pelas forças inerentes mucocilárias que estão presentes na cavidade nasal, um processo de uso da composição e um processo de preparação da composição, incluindo na forma preferida o uso de esteróide antiinflamatório, por exemplo, triancinolona acetonida, e uma forma inodora da composição.
BRPI9710115-0A 1996-07-03 1997-07-02 composiÇço aquosa farmacÊutica, e processo de preparaÇço de uma composiÇço aquosa farmacÊutica. BR9710115B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/678,465 US5976573A (en) 1996-07-03 1996-07-03 Aqueous-based pharmaceutical composition
US08/678465 1996-07-03
PCT/US1997/011462 WO1998000178A1 (en) 1996-07-03 1997-07-02 Aqueous-based pharmaceutical composition

Publications (2)

Publication Number Publication Date
BR9710115A true BR9710115A (pt) 2000-01-11
BR9710115B1 BR9710115B1 (pt) 2010-12-14

Family

ID=24722901

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9710115-0A BR9710115B1 (pt) 1996-07-03 1997-07-02 composiÇço aquosa farmacÊutica, e processo de preparaÇço de uma composiÇço aquosa farmacÊutica.

Country Status (26)

Country Link
US (8) US5976573A (pt)
EP (2) EP0938345B1 (pt)
JP (1) JP2001501914A (pt)
KR (1) KR100383601B1 (pt)
CN (1) CN1235568C (pt)
AP (1) AP1045A (pt)
AT (1) ATE250432T1 (pt)
AU (1) AU737506C (pt)
BG (1) BG64585B1 (pt)
BR (1) BR9710115B1 (pt)
CA (1) CA2268927C (pt)
CZ (1) CZ299689B6 (pt)
DE (1) DE69725161T2 (pt)
DK (1) DK0938345T3 (pt)
EA (1) EA001406B1 (pt)
ES (1) ES2208931T3 (pt)
HU (1) HU227993B1 (pt)
IL (1) IL127611A0 (pt)
NO (1) NO318241B1 (pt)
OA (1) OA10950A (pt)
PL (1) PL194269B1 (pt)
PT (1) PT938345E (pt)
SK (1) SK284491B6 (pt)
UA (1) UA68337C2 (pt)
WO (1) WO1998000178A1 (pt)
ZA (1) ZA975947B (pt)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976573A (en) * 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
DE19653969A1 (de) * 1996-12-20 1998-06-25 Boehringer Ingelheim Kg Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole
US20030215396A1 (en) * 1999-09-15 2003-11-20 Boehringer Ingelheim Pharma Kg Method for the production of propellant gas-free aerosols from aqueous medicament preparations
GB9701552D0 (en) * 1997-01-25 1997-03-12 Bristol Myers Squibb Co Multi-dose wound gel
US20030095927A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders
US20040136913A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing sumatriptan
US20040136915A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing atropine
US20040136914A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing ondansetron
US20050287075A1 (en) * 1997-10-01 2005-12-29 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US20030185761A1 (en) * 1997-10-01 2003-10-02 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US20030077229A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
US20030095926A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
US20030077228A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating endocrine disorders
US20050163719A1 (en) * 1997-10-01 2005-07-28 Dugger Harry A.Iii Buccal, polar and non-polar spray containing diazepam
US20040141923A1 (en) * 1997-10-01 2004-07-22 Dugger Harry A. Buccal, polar and non-polar spray containing alprazolam
US20030095925A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
US20050180923A1 (en) * 1997-10-01 2005-08-18 Dugger Harry A.Iii Buccal, polar and non-polar spray containing testosterone
US20050002867A1 (en) * 1997-10-01 2005-01-06 Novadel Pharma Inc. Buccal, polar and non-polar sprays containing propofol
US20030190286A1 (en) * 1997-10-01 2003-10-09 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma
US20030082107A1 (en) * 1997-10-01 2003-05-01 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer
EP1952802A3 (en) * 1997-10-01 2009-06-17 Novadel Pharma Inc. Buccal, polar and non-polar spray or capsule
US7632517B2 (en) 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
TWI243687B (en) * 1998-04-21 2005-11-21 Teijin Ltd Pharmaceutical composition for application to mucosa
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US6576224B1 (en) * 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
AR026073A1 (es) 1999-10-20 2002-12-26 Nycomed Gmbh Composicion farmaceutica acuosa que contiene ciclesonida
US6565832B1 (en) * 2000-01-31 2003-05-20 Schering-Plough Healthcare Products, Inc. Spray composition with reduced dripping
US20020013331A1 (en) * 2000-06-26 2002-01-31 Williams Robert O. Methods and compositions for treating pain of the mucous membrane
US20030072717A1 (en) * 2001-02-23 2003-04-17 Vapotronics, Inc. Inhalation device having an optimized air flow path
US20030064052A1 (en) * 2001-05-21 2003-04-03 Ponwell Enterprises, Ltd. Compositions for protein delivery via the pulmonary route
BG65734B1 (bg) * 2002-02-22 2009-09-30 Био Терапютикс - Еоод Течен мукоадхезивен фармацевтичен състав
US6641799B2 (en) 2002-04-03 2003-11-04 Nos Spray, Inc. Nasal spray for decongesting nasal passages
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
EP1374856A1 (en) * 2002-06-18 2004-01-02 Impetus AG Oily thixotropic nasal spray
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
WO2004024187A2 (en) * 2002-09-13 2004-03-25 Zicam, Llc. Compositions to reduce congestion and methods for application thereof to the nasal membrane
EP1560586A1 (en) * 2002-11-12 2005-08-10 Alcon, Inc. The use of an anti-allergy agent and a steroid to treat allergic rhinitis
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
ATE463257T1 (de) * 2003-01-13 2010-04-15 Procter & Gamble Zusammensetzungen zur vorbeugung und behandlung von erkältung und influenza-ähnlichen erscheinungen enthaltend ausgewählte mukadhäsive polymere
US9808471B2 (en) * 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
US8912174B2 (en) * 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US7811606B2 (en) * 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
EP1663999A2 (en) * 2003-08-29 2006-06-07 Ranbaxy Laboratories, Ltd. Inhibitors of phosphodiesterase type-iv
US20050058673A1 (en) * 2003-09-09 2005-03-17 3M Innovative Properties Company Antimicrobial compositions and methods
US20070259874A1 (en) * 2003-11-26 2007-11-08 Palle Venkata P Phosphodiesterase Inhibitors
WO2005065185A2 (en) * 2003-12-24 2005-07-21 Collegium Pharmaceuticals, Inc. Temperature-stable formulations, and methods of development thereof
US7361168B2 (en) 2004-04-21 2008-04-22 Acclarent, Inc. Implantable device and methods for delivering drugs and other substances to treat sinusitis and other disorders
SE0401031D0 (sv) 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
US20060051384A1 (en) * 2004-09-07 2006-03-09 3M Innovative Properties Company Antiseptic compositions and methods of use
US8198326B2 (en) * 2004-09-07 2012-06-12 3M Innovative Properties Company Phenolic antiseptic compositions and methods of use
US9028852B2 (en) * 2004-09-07 2015-05-12 3M Innovative Properties Company Cationic antiseptic compositions and methods of use
PL1814538T3 (pl) * 2004-11-24 2010-02-26 Alcon Inc Sposób dostarczania donosowego sprayu
ES2704482T3 (es) 2004-11-24 2019-03-18 Meda Pharmaceuticals Inc Composiciones que comprenden azelastina y sus métodos de uso
KR100666220B1 (ko) * 2005-01-31 2007-01-09 영남대학교 산학협력단 구내염 치료용 분사제 조성물
EP1858506A2 (en) * 2005-03-10 2007-11-28 3M Innovative Properties Company Methods of treating ear infections
JP5642929B2 (ja) * 2005-03-10 2014-12-17 スリーエム イノベイティブ プロパティズ カンパニー 微小生体汚染の低減方法
ATE511838T1 (de) * 2005-03-10 2011-06-15 3M Innovative Properties Co Antimikrobielle zusammensetzungen mit hydroxycarboxylsäureestern
US7851419B2 (en) * 2005-09-12 2010-12-14 Nawaz Ahmad Substantially anhydrous sprayable personal lubricant
US20070059250A1 (en) * 2005-09-12 2007-03-15 Nawaz Ahmad Sprayable personal lubricant
US7915286B2 (en) 2005-09-16 2011-03-29 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
CA2626628A1 (en) * 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type iv inhibitors
US20090221664A1 (en) 2005-10-19 2009-09-03 Abhijit Ray Pharmaceutical compositions of muscarinic receptor antagonists
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8497258B2 (en) * 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
US20070231396A1 (en) * 2006-03-29 2007-10-04 Ray Charles D Medication spray formulation
EP2066661A2 (en) * 2006-09-22 2009-06-10 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
CN101616901A (zh) * 2006-09-22 2009-12-30 兰贝克赛实验室有限公司 Iv型磷酸二酯酶的抑制剂
WO2008057773A2 (en) 2006-10-27 2008-05-15 3M Innovative Properties Company Antimicrobial compositions
EP1958947A1 (en) 2007-02-15 2008-08-20 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type 4
KR20080076667A (ko) * 2007-02-15 2008-08-20 주식회사 중외제약 요변성 약학 조성물
PL2124944T3 (pl) 2007-03-14 2012-08-31 Sun Pharmaceutical Ind Ltd Pochodne pirazolo[3,4-b]pirydyny jako inhibitory fosfodiesterazy
EP2124943A1 (en) * 2007-03-14 2009-12-02 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b]pyridine derivatives as phosphodiesterase inhibitors
WO2008141264A1 (en) * 2007-05-10 2008-11-20 Novadel Pharma Inc. Anti-insomnia compositions and methods
EP2111861A1 (en) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
WO2010052575A2 (en) 2008-11-10 2010-05-14 Scandivir Ab Ngna compositions and methods of use
US10350233B2 (en) 2009-04-06 2019-07-16 Joshua D. Levine Method of treating and preventing neuro-olfactory triggered or aggravated illnesses or related conditions
WO2010118028A1 (en) 2009-04-06 2010-10-14 Levine Joshua D Method of treating and preventing neuro-olfactory triggered or aggravated illnesses or related conditions
US8894630B2 (en) * 2009-11-13 2014-11-25 The Invention Science Fund I, Llc Device, system, and method for targeted delivery of anti-inflammatory medicaments to a mammalian subject
US8439896B2 (en) * 2009-11-13 2013-05-14 The Invention Science Fund I, Llc Device, system, and method for targeted delivery of anti-inflammatory medicaments to a mammalian subject
US9078863B2 (en) * 2009-11-13 2015-07-14 The Invention Science Fund I, Llc Device, system, and method for targeted delivery of anti-inflammatory medicaments to a mammalian subject
US20120000941A1 (en) * 2010-06-30 2012-01-05 Inspire Pharmaceuticals, Inc. Medicine dispenser
CN103327939B (zh) 2010-10-15 2017-05-24 科尼尔赛德生物医学公司 用于进入眼睛的装置
CN103269687B (zh) * 2011-01-04 2016-09-14 伊斯塔制药公司 贝托斯汀组合物
FR2970180B1 (fr) * 2011-01-06 2013-08-02 Substipharm Dev Procede de preparation de suspensions aqueuses pharmaceutiques comprenant un medicament efficace dans le traitement des rhinites
US9181185B2 (en) 2011-10-31 2015-11-10 Purdue Pharma L.P. Heteroaryl compounds as sodium channel blockers
MX389676B (es) * 2012-11-08 2025-03-20 Clearside Biomedical Inc Metodos y dispositivos para el tratamiento de trastornos oculares en sujetos humanos
EP4378444A3 (en) 2013-05-03 2024-07-03 Clearside Biomedical, Inc. Apparatus and methods for ocular injection
WO2014197317A1 (en) 2013-06-03 2014-12-11 Clearside Biomedical, Inc. Apparatus and methods for drug delivery using multiple reservoirs
WO2017023162A1 (en) * 2015-08-04 2017-02-09 Inqpharm Group Sdn Bhd A nasal composition
US20170121098A1 (en) * 2015-11-02 2017-05-04 American Sterilizer Company Non-aspirating transport gel dispenser
US10390901B2 (en) 2016-02-10 2019-08-27 Clearside Biomedical, Inc. Ocular injection kit, packaging, and methods of use
EP3452165A1 (en) 2016-05-02 2019-03-13 Clearside Biomedical, Inc. Systems and methods for ocular drug delivery
US10973681B2 (en) 2016-08-12 2021-04-13 Clearside Biomedical, Inc. Devices and methods for adjusting the insertion depth of a needle for medicament delivery
WO2018204515A1 (en) 2017-05-02 2018-11-08 Georgia Tech Research Corporation Targeted drug delivery methods using a microneedle
WO2019073298A1 (en) 2017-10-11 2019-04-18 Lifescience As N-acetylneuraminic acid compositions and methods of use
US12036329B2 (en) 2018-09-11 2024-07-16 Lead Biotherapeutics Ltd Mucoadhesive dispersion nanoparticle system and method for production the same
KR20220161413A (ko) 2020-04-01 2022-12-06 라이프사이언스 에이에스 코로나바이러스 감염의 억제 및 치료에 사용하기 위한 시알산 조성물

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2156254A (en) * 1937-10-29 1939-04-25 Piedmont Dev Corp Therapeutic composition
US2186254A (en) * 1939-03-31 1940-01-09 Westinghouse Electric & Mfg Co Multispeed motor control
US3035984A (en) * 1958-08-26 1962-05-22 Wallace & Tiernan Inc Dihydrocodeinone resin complex suspensions
US3035064A (en) * 1958-10-15 1962-05-15 Roussel Uclaf 18-11 lactone of 3-oxygenated 11beta-hydroxy-13, 17-seco-etiocholane-17, 18-dioic acid and its esters and processes for their production
US3829794A (en) * 1971-03-04 1974-08-13 Lambda Electronics Corp Circuit for reducing the direct current component of an alternating current output signal
US3780176A (en) * 1971-10-05 1973-12-18 American Cyanamid Co Predominantly aqueous substituted triamcinolone compositions
US3809294A (en) * 1973-06-27 1974-05-07 American Cyanamid Co Dispensing lung contacting powdered medicaments
US3897779A (en) * 1973-06-27 1975-08-05 American Cyanamid Co Triamcinolone acetonide inhalation therapy
US4933168A (en) * 1975-05-27 1990-06-12 Syntex Pharmaceuticals International Limited Stable, crystalline flunisolide
US4405598A (en) * 1976-01-30 1983-09-20 Fisons, Limited Composition for treating asthma
GB2042888B (en) * 1979-03-05 1983-09-28 Teijin Ltd Preparation for administration to the mucosa of the oral or nasal cavity
US4280163A (en) * 1979-03-05 1981-07-21 Homexx International Corp. Electronic lock
US4407792A (en) * 1979-05-09 1983-10-04 Alcon Laboratories, Inc. Sustained release ophthalmic drug dosage
JPS6034925B2 (ja) * 1979-07-31 1985-08-12 帝人株式会社 持続性鼻腔用製剤およびその製造法
CA1201114A (en) * 1980-02-15 1986-02-25 Gordon H. Phillipps Androstane carbothioates
US4304765A (en) * 1980-10-14 1981-12-08 Alza Corporation Ocular insert housing steroid in two different therapeutic forms
DE3046584C2 (de) * 1980-12-11 1984-03-15 Dr.-Ing. Rudolf Hell Gmbh, 2300 Kiel Optisch-mechanischer Abtaster
IT1194068B (it) * 1981-05-20 1988-09-14 Getters Spa Linguetta di supporto perfezionata per dispositivi getter
EP0073357A3 (en) 1981-08-19 1984-02-22 NESPAK S.p.A. Società Generale per L'Imballaggio Assemblable and stackable crate of plastic material and apparatus for assembling same
US4432964A (en) * 1981-08-24 1984-02-21 Alza Corporation Topical composition containing steroid in two forms released independently from polymeric carrier
US4443440A (en) * 1982-08-30 1984-04-17 The Upjohn Company Amine containing ester prodrugs of corticosteroids
US4427681A (en) * 1982-09-16 1984-01-24 Richardson-Vicks, Inc. Thixotropic compositions easily convertible to pourable liquids
US4478818A (en) * 1982-12-27 1984-10-23 Alza Corporation Ocular preparation housing steroid in two different therapeutic forms
FR2546407B1 (fr) * 1983-05-24 1986-04-18 Therapeutique Applic Sa Medicament a activite anti-allergique pour administration locale a base d'acide n-acetyl(a,b)-aspartyl glutamique
EP0187433B1 (en) * 1983-08-01 1990-12-27 Teijin Limited Powdery pharmaceutical composition suitable for application to mucosa of oral or nasal cavity
JPS6032714A (ja) * 1983-08-01 1985-02-19 Teijin Ltd 鼻腔粘膜に適用するための安定化された粉末状薬学的組成物
US4983595A (en) * 1986-05-22 1991-01-08 Syntex (U.S.A.) Inc. Aqueous steroid formulations for nasal administration
US4782047A (en) * 1986-05-22 1988-11-01 Syntex Pharmaceuticals International Ltd. Aqueous steroid formulations for nasal administration
ES2058129T3 (es) * 1986-12-23 1994-11-01 Fisons Plc Composiciones farmaceuticas que comprenden una solucion acuosa de un derivado de piranoquinolina.
US4767612A (en) * 1987-01-23 1988-08-30 Rorer Pharmaceutical Corporation Triamcinolone acetonide for the treatment of allergic rhinitis
DE3877904D1 (de) 1987-11-13 1993-03-11 Asta Pharma Ag Azelastin enthaltende arzneimittel zur anwendung in der nase und/oder am auge.
JPH01294620A (ja) 1988-05-19 1989-11-28 Kissei Pharmaceut Co Ltd 水溶液製剤およびその製造方法
JP2546347B2 (ja) * 1988-08-15 1996-10-23 日本電気株式会社 無線送受信装置
US5461081A (en) * 1989-09-28 1995-10-24 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
US5439670A (en) * 1989-11-28 1995-08-08 Riker Laboratories, Inc. Medicinal aerosol formulations
US5124154A (en) * 1990-06-12 1992-06-23 Insite Vision Incorporated Aminosteroids for ophthalmic use
HU213401B (en) 1990-09-10 1997-06-30 Schering Corp Process for producing mometasone furoate monohydrate and pharmaceutical composition containing it
US5300302A (en) * 1990-10-04 1994-04-05 Nestec S.A. Pharmaceutical composition in gel form in a dispensing package
SE466134B (sv) * 1990-11-22 1992-01-07 Kabi Pharmacia Ab Gelbildande flytande baerarkomposition samt anvaendning daerav i farmaceutiska kompositioner
GB9102579D0 (en) * 1991-01-24 1991-03-27 Glaxo Group Ltd Compositions
GB9103824D0 (en) * 1991-02-23 1991-04-10 Fisons Ag Formulation
ATE171865T1 (de) 1991-12-12 1998-10-15 Glaxo Group Ltd Arzneimittel
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
DE4221256C2 (de) * 1992-06-26 1997-07-10 Lancaster Group Ag Galenische Zusammensetzung für die topische Anwendung
GB9218834D0 (en) * 1992-09-05 1992-10-21 Procter & Gamble Nasal spray products
US5429824A (en) * 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
TW401300B (en) * 1992-12-25 2000-08-11 Senju Pharma Co Antiallergic composition for ophthalmic or nasal use
US5425952A (en) * 1993-10-13 1995-06-20 Church & Dwight Co., Inc. Slow-release ammonium bicarbonate fungicide compositions
US5540930A (en) * 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
US5543434A (en) * 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
JP3021312B2 (ja) 1994-03-15 2000-03-15 千寿製薬株式会社 プラノプロフェンの安定化方法および安定なプラノプロフェン水性液剤
US5389386A (en) * 1994-06-30 1995-02-14 Church & Dwight Co., Inc. Method of controlling fungal disease in cultivated plants
EP0806940B1 (en) 1994-12-22 2003-04-09 AstraZeneca AB Aerosol drug formulations
IT1275955B1 (it) * 1995-03-22 1997-10-24 Dompe Spa Formulazioni farmaceutiche in forma di gel tissotropico
EP0780127A1 (en) * 1995-12-19 1997-06-25 The Procter & Gamble Company A nasal spray containing a steroid and a antihistamine
AU3153797A (en) * 1996-06-04 1998-01-05 Procter & Gamble Company, The A nasal spray containing an intranasal steroid and an antihistamine
US5976573A (en) 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition

Also Published As

Publication number Publication date
HUP9903503A3 (en) 2000-06-28
HUP9903503A2 (hu) 2000-04-28
HK1022652A1 (en) 2000-08-18
CN1228712A (zh) 1999-09-15
US5976573A (en) 1999-11-02
PL194269B1 (pl) 2007-05-31
US7122206B2 (en) 2006-10-17
HU227993B1 (hu) 2012-08-28
EP1382330A1 (en) 2004-01-21
ES2208931T3 (es) 2004-06-16
UA68337C2 (uk) 2004-08-16
ATE250432T1 (de) 2003-10-15
OA10950A (en) 2002-02-18
US20090124586A1 (en) 2009-05-14
DE69725161T2 (de) 2004-06-09
WO1998000178A1 (en) 1998-01-08
CN1235568C (zh) 2006-01-11
ZA975947B (en) 1998-05-11
CZ437798A3 (cs) 2000-01-12
CA2268927A1 (en) 1998-01-08
US6375984B1 (en) 2002-04-23
US6143329A (en) 2000-11-07
AP9901495A0 (en) 1999-06-30
BG103127A (en) 1999-09-30
AU3647197A (en) 1998-01-21
CA2268927C (en) 2003-09-23
BR9710115B1 (pt) 2010-12-14
US7977045B2 (en) 2011-07-12
SK284491B6 (sk) 2005-05-05
US20070031887A1 (en) 2007-02-08
EP0938345A4 (en) 1999-12-29
BG64585B1 (bg) 2005-08-31
DK0938345T3 (da) 2004-01-12
IL127611A0 (en) 1999-10-28
EA199900080A1 (ru) 1999-06-24
DE69725161D1 (de) 2003-10-30
SK181698A3 (en) 2000-06-12
US20030049322A1 (en) 2003-03-13
US20100222314A1 (en) 2010-09-02
PT938345E (pt) 2004-02-27
NO986023L (no) 1999-02-15
EP0938345B1 (en) 2003-09-24
US20110230455A1 (en) 2011-09-22
PL330936A1 (en) 1999-06-07
CZ299689B6 (cs) 2008-10-22
NO318241B1 (no) 2005-02-21
AU737506C (en) 2002-03-21
AU737506B2 (en) 2001-08-23
EA001406B1 (ru) 2001-02-26
KR100383601B1 (ko) 2003-05-14
EP0938345A1 (en) 1999-09-01
KR20000023563A (ko) 2000-04-25
JP2001501914A (ja) 2001-02-13
NO986023D0 (no) 1998-12-21
AP1045A (en) 2002-02-19

Similar Documents

Publication Publication Date Title
BR9710115A (pt) Processo para aplicar partìculas sólidas de um medicamento em superfìcies de mucosa das cavidade nasais, composição aquosa farmacêutica, e , processo de preparação de uma composição aquosa farmacêutica.
BR9913945A (pt) Composição farmacêutica para o tratamento de distúrbios agudos por meio de administração sublingual, e, processo para o tratamento de distúrbios agudos
BRPI0410260A (pt) composição conjugada para medicamento
SE9003712L (sv) Gelbildande flytande baerarkomposition samt anvaendning daerav i farmaceutiska kompositioner
BR9910851A (pt) Composição de tratamento para os cabelos.
BR9507164A (pt) Composiçao farmacêutica em forma de gel para o tratamento de distúrbios da pele processo de tratamento de pele e uso de uma combinaçao de um agente gelificante de polimero e um alcanol inferior de etil hidroxietil celulose e de um alcanol inferior
ES2167453T3 (es) Composicion de suministro medicamentoso que contiene quitosano o derivado del mismo con un potencial z. definido.
ES2122217T3 (es) Composiciones cosmeticas que contienen nanocapsulas.
BR9916694A (pt) Composição de lenço facial e método de uso parasequestração de irritantes cutâneos de secreçãonasal
BR9808812A (pt) Composição compreendendo partìculas cristalinas, finamente divididas de budesonida
GB2288734A (en) Sprayable pharmaceutical-gel compositions for topical use
BR9906372A (pt) Composição farmaceutica aquosa para aplicação na mucosa
BR9808888A (pt) Formas de dosagem e método de melhorar disfunção erétil masculina
ID26221A (id) Komposisi-komposisi farmasi yang dapat dijadikan gel
EP0336902A3 (en) Antiinflammatory skin moisturizing composition and method of preparing same
BR9709097A (pt) Composição farmacêutica para o tratamento de doenças mediadas por ciclooxigenase processo para tratar uma doença inflamatória suscetível de tratamento com um agente antinflamatório n o esteróide uso e forma oral de dose unitária
BRPI9509286B8 (pt) microcápsulas medicamentosas e/ou nutricionais para administração per si.
AR005679A1 (es) Composiciones suavizantes de la piel que contienen hidroxiacidos y metodos para su utilizacion.
BR9813811A (pt) "composições farmacêuticas compreendendo micelas que compreendem glicocorticosteróide lipofìlico e apenas um único tensoativo"
BRPI0408599A (pt) produtos de confeitaria para distribuição de agentes farmaceuticamente ativos para a garganta
AR012621A1 (es) Composiciones organicas
BR9910329A (pt) Composto, composição farmacêutica, processo para estimular a liberação do hormÈnio de crescimento da pituitária de um mamìfero, e, uso de um composto
JPS6431707A (en) Dermal agent for external use
BR9813514A (pt) Agente para tratamento de fibras queratìnicas
CO5261494A1 (es) Composiciones farmaceuticas acuosas e hipotonicas de ciclesonida que presentan absorcion nasal mejorada

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved
B25A Requested transfer of rights approved

Owner name: AVENTIS PHARMACEUTICALS INC. (US)

Free format text: TRANSFERIDO POR INCORPORACAO DE: AVENTIS PHARMACEUTICALS HOLDINGS INC.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: REFERENTE A RPI 1967 DE 16/09/2008

B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: REFERENTE A RPI 1971 DE 14/10/2008

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 14/12/2010, OBSERVADAS AS CONDICOES LEGAIS.

B25A Requested transfer of rights approved

Owner name: AVENTISUB LLC. (US)

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 14.12.2020